MA47408B1 - Traitement du cancer - Google Patents

Traitement du cancer

Info

Publication number
MA47408B1
MA47408B1 MA47408A MA47408A MA47408B1 MA 47408 B1 MA47408 B1 MA 47408B1 MA 47408 A MA47408 A MA 47408A MA 47408 A MA47408 A MA 47408A MA 47408 B1 MA47408 B1 MA 47408B1
Authority
MA
Morocco
Prior art keywords
cancer treatment
erdafitinib
relates
present
treating cancer
Prior art date
Application number
MA47408A
Other languages
English (en)
Other versions
MA47408A (fr
Inventor
Kim Stuyckens
Ruixo Juan Perez
Porre Peter De
Anjali Avadhani
Yohann Loriot
Arlene Siefker-Radtke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47408A publication Critical patent/MA47408A/fr
Publication of MA47408B1 publication Critical patent/MA47408B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de traitement du cancer par l'erdafitinib
MA47408A 2017-12-20 2018-02-02 Traitement du cancer MA47408B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (fr) 2017-02-06 2018-02-02 Traitement du cancer

Publications (2)

Publication Number Publication Date
MA47408A MA47408A (fr) 2019-12-11
MA47408B1 true MA47408B1 (fr) 2023-08-31

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47408A MA47408B1 (fr) 2017-12-20 2018-02-02 Traitement du cancer

Country Status (5)

Country Link
EA (1) EA201991818A1 (fr)
MA (1) MA47408B1 (fr)
PT (1) PT3576740T (fr)
TW (1) TWI798199B (fr)
WO (1) WO2018141921A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210064274A (ko) * 2018-09-21 2021-06-02 얀센 파마슈티카 엔.브이. 담관암종의 치료
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
WO2020131627A1 (fr) 2018-12-19 2020-06-25 Array Biopharma Inc. Composés pyrazolo[1,5-a]pyridine substitués servant d'inhibiteurs de tyrosine kinases fgfr
BR112021015686A2 (pt) * 2019-02-12 2021-10-26 Janssen Pharmaceutica N.V. Tratamento de câncer
US20220202703A1 (en) * 2019-03-15 2022-06-30 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
MX2021011926A (es) 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
US20220175768A1 (en) * 2019-03-29 2022-06-09 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CN114207151A (zh) * 2019-05-31 2022-03-18 Qed医药股份有限公司 治疗泌尿系统癌症的方法
WO2021119108A1 (fr) * 2019-12-09 2021-06-17 Cedars-Sinai Medical Center Utilisation d'inhibiteurs de fgfr pour le traitement de sujets présentant un retard de croissance idiopathique
TWI900527B (zh) * 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
PH12022552093A1 (en) * 2020-02-12 2023-11-29 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
CA3195543A1 (fr) * 2020-09-17 2022-03-24 Ayala Pharmaceuticals Inc. Compositions comprenant des composes de bisfluoroalkyl-1,4-benzodiazepinone pour traiter un carcinome adenoide kystique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物

Also Published As

Publication number Publication date
EA201991818A1 (ru) 2020-02-05
MA47408A (fr) 2019-12-11
PT3576740T (pt) 2023-08-18
TWI798199B (zh) 2023-04-11
TW201839399A (zh) 2018-11-01
WO2018141921A1 (fr) 2018-08-09

Similar Documents

Publication Publication Date Title
MX2023007581A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
IL283838A (en) Method of treating cancer with a cancer therapy in combination with another therapeutic agent
EP3813806A4 (fr) Méthodes de traitement d'un dysfonctionnement mitochondrial
MA49760B1 (fr) Mavacamten pour l'utilisation dans le traitement de la cardiomyopathie hypertrophique
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
MX373154B (es) Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
EP3820461A4 (fr) Méthode de traitement du cancer
MA51418A (fr) Inhibiteurs de glycolate oxydase pour le traitement de maladies
EP3580185A4 (fr) Procédé de traitement de boue
MA46459A (fr) Méthode de traitement de lésions rénales aiguës
EP3937964A4 (fr) Traitement de cancers induits par des oncogènes
EA201991818A1 (ru) Лечение рака
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
EP3775171A4 (fr) Procédés de traitement d'un cancer résiduel minimal
EP3684342A4 (fr) Procédé de traitement
EP3769897A4 (fr) Machine de traitement par laser et procédé de traitement par laser
EA201792610A1 (ru) Способ лечения неврологического заболевания
EP3672689A4 (fr) Procédé de traitement d'une tumeur neuroendocrine
EP3952858A4 (fr) Procédé de traitement de tumeurs
EP3638630A4 (fr) Procédé de traitement de boues
EP3787625A4 (fr) Méthodes de traitement du cancer
EP3947296A4 (fr) Procédé de traitement des eaux usées
EP3407858A4 (fr) Méthode de traitement de l'aspect dégarni des cheveux
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
EP3962524A4 (fr) Traitement du cancer